Key Points
- Heartflow insider Campbell Rogers sold 9,219 shares at an average price of $41.23, generating approximately $380,099. The transaction, conducted under a Rule 10b5-1 plan, reduced Rogers’ holdings by 9.64%.
- Heartflow reported quarterly revenue of $64.08 million, up 47.7% year over year, while adjusted EPS of -$0.07 exceeded the consensus estimate of -$0.22. The company remains unprofitable, with a negative net margin of 55.82%.
- Analysts maintain a generally positive outlook, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $43.43. Shares opened at $45.53, near the 52-week high of $47.23.
Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) insider Campbell Rogers sold 9,219 shares of the firm's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $41.23, for a total transaction of $380,099.37. Following the sale, the insider owned 86,459 shares of the company's stock, valued at $3,564,704.57. This represents a 9.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Heartflow Stock Up 0.7%
NASDAQ:HTFL opened at $45.53 on Thursday. The stock's fifty day moving average is $30.00 and its two-hundred day moving average is $28.05. Heartflow, Inc. has a 52 week low of $20.13 and a 52 week high of $47.23. The stock has a market capitalization of $3.96 billion and a price-to-earnings ratio of -24.88.
Heartflow (NASDAQ:HTFL - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.The firm had revenue of $64.08 million during the quarter. Heartflow's revenue for the quarter was up 47.7% on a year-over-year basis. On average, sell-side analysts expect that Heartflow, Inc. will post -0.82 EPS for the current fiscal year.
Institutional Investors Weigh In On Heartflow
A number of institutional investors have recently modified their holdings of the business. XXEC Inc. bought a new position in Heartflow in the 2nd quarter worth about $2,524,764,000. BlackRock Inc. acquired a new stake in Heartflow during the 2nd quarter worth about $152,502,000. Wellington Management Group LLP purchased a new stake in shares of Heartflow in the 3rd quarter valued at approximately $164,263,000. Bamco Inc. NY acquired a new stake in shares of Heartflow in the second quarter worth $94,625,000. Finally, Jupiter Topco LLC acquired a new stake in Heartflow during the 2nd quarter worth about $70,983,000.
Analyst Ratings Changes
A number of equities research analysts have weighed in on HTFL shares. Morgan Stanley lifted their price objective on Heartflow from $35.00 to $40.00 and gave the company an "equal weight" rating in a report on Friday, August 14th. Piper Sandler restated an "overweight" rating and set a $45.00 target price (up from $38.00) on shares of Heartflow in a report on Friday, August 14th. Freedom Capital raised Heartflow to a "strong-buy" rating in a report on Tuesday, June 30th. Robert W. Baird set a $45.00 price objective on shares of Heartflow in a research report on Friday, August 14th. Finally, Wells Fargo & Company increased their target price on Heartflow from $37.00 to $39.00 and gave the stock an "overweight" rating in a research report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $43.43.
Check Out Our Latest Stock Analysis on Heartflow
Heartflow Company Profile
(
Get Free Report)
HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.
HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
